News
Gilead looks beyond Trodelvy with Tubulis alliance
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
News
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
News
Novartis pays $1bn upfront for Huntington's drug from PTC
Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.
News
Alligator slashes workforce and pares down its pipeline
Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce.
News
Abingworth 'will launch $1.5bn fund for co-developed drugs'
Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
